|
Press Release
Bruker Daltonics and Protein Discovery Announce MALDI Molecular Imaging Mass Spectrometry Co-Marketing Agreement
BILLERICA, Mass. & KNOXVILLE, Tenn.(BUSINESS WIRE) May 30, 2006—Bruker Daltonics Inc. and Protein Discovery, Inc. announce today that they intend to collaborate on introducing scientists to the protein biomarker discovery capabilities of MALDI molecular imaging mass spectrometry. Protein Discovery holds a license from Vanderbilt University to provide imaging mass spectrometry services, and provides these services to customers in the research, pharmaceutical and diagnostics industries. Bruker Daltonics manufactures and sells the MALDI Molecular Imager™ (for research use only) that has been optimized for this technique in collaboration with Professor Richard Caprioli at Vanderbilt University. Both companies anticipate significant synergy effects from the collaboration, as both expect to benefit from the increasing popularity of MALDI imaging mass spectrometry.
MALDI molecular imaging mass spectrometry reads cell type specific protein and peptide mass spectra directly from sliced tissues. The imaging resolution of the technique enables differential mass spectrometry analysis of adjacent tissue types within a single tissue slice, such as cancerous vs. non-cancerous regions. MALDI imaging mass spectrometry is very promising for research and discovery of future diagnostic and prognostic protein biomarkers.
Protein Discovery's MALDI imaging mass spectrometry service laboratory is outfitted with Bruker Daltonics' instrumentation. "The capabilities and applications of MALDI imaging mass spectrometry have now been well documented in the scientific literature by researchers who picked up on it early," said Chuck Witkowski, chief executive officer at Protein Discovery. "However, until recently, there was little vendor support for imaging mass spectrometry, so biologists and research clinicians couldn't really see what the technique could accomplish for their own research. With the Bruker Daltonics MALDI Molecular Imager we now can show them the power of this new technique on their own research samples. We're already conducting a number of pilot-scale projects for research groups looking for cell type specific protein spectra that they can map directly onto a histological tissue slice image."
Dr. Michael Schubert, Executive Vice President of Bruker Daltonics, stated: "Our recently introduced MALDI Molecular Imager is the leading mass spectrometry platform for imaging the spatial distribution of peptide and protein biomarkers in tissue sections. Enabled by our unique and proprietary smartbeam(TM) technology, the MALDI Molecular Imager generates results very quickly and with unrivalled data quality. Visualization of the spatial distribution of peptides and proteins is a powerful new tool in the fields of biomarker validation and drug development. Protein Discovery has significant expertise in applying MALDI molecular imaging mass spectrometry and we are very pleased to enter into this partnership with them."
ABOUT PROTEIN DISCOVERY
Protein Discovery, Inc. develops and markets mass spectrometry sample preparation products and services. The company's solutions simplify sample preparation, increase sample throughput, improve data quality, and accelerate the development and adoption of mass spectrometry as a routine analytical and clinical technique. Protein Discovery is privately held and located in Knoxville, Tennessee. For additional information, please visit www.proteindiscovery.com.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bdal.com and www.bruker-biosciences.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.
All products are for research use only.
MULTIMEDIA AVAILABLE
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5158346
CONTACT
|
Bruker Daltonics Inc.
Michael Willett,
Investor & Public Relations Officer
978-663-3660, ext. 1411
|
 |
Protein Discovery, Inc.
Chuck Witkowski,
CEO
865-521-7400
|
TOP 
|
|
